Allergan's revenue and adjusted EPS figures for Q2 beat market estimates, sending shares up by about 0.7% in premarket trade. The pharma company reported a 2.9% improvement in revenues to $4.12 billion for the second quarter of 2018 compared to the prior year period, driven by a 10.6% increase in its core business which includes the Botox and Juvederm brands.
Infographics of the company's results can be found at https://news.alphastreet.com/allergan-posts-upbeat-results-earnings-q2-2018/
Infographics of the company's results can be found at https://news.alphastreet.com/allergan-posts-upbeat-results-earnings-q2-2018/